チロシンキナーゼ阻害剤の世界市場レポート 2025年

チロシンキナーゼ阻害剤の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.8％で887億4,000万米ドルに成長します。予測期間の成長は、ヘルスケア投資の拡大、バイオマーカー主導の治療法、ドラッグデリバリーの革新、精密医療のパラダイム、小児がん領域への注力などに起因すると考えられます。予測期間における主な動向としては、耐性緩和戦略、中枢神経系透過性の開発、非がん領域への応用、モニタリング用リキッドバイオプシー、医療経済への配慮などが挙げられます。

予想されるがん罹患率の上昇が、今後のチロシンキナーゼ阻害剤市場の成長を牽引します。がんは、制御不能な細胞増殖を特徴とする多様な疾患群であり、異常細胞が増殖し、近隣組織に浸潤し、他の臓器に転移する可能性があるため、健康上の重大な課題となります。チロシンキナーゼ阻害剤は、特定のチロシンキナーゼを阻害することで、がん細胞の増殖を抑制し、標的治療において重要な役割を果たしています。2023年1月現在、米国がん協会によると、がん罹患者数は2021年の1,898,160人から2023年には1,958,310人へと3.16％増加します。このがん患者の急増は、チロシンキナーゼ阻害剤市場の成長を促進する主要な要因です。

チロシンキナーゼ阻害剤市場の成長を牽引しているのは、ヘルスケア支出の増加です。ヘルスケア支出とは、特定の地域、国、組織内のヘルスケア部門に割り当てられている総財源を指します。この支出は、特定のがん種やその他の疾患に対する標的療法であるチロシンキナーゼ阻害剤の開発と使用を支えています。例えば、2024年9月、米国を拠点とするABAセラピー・サービスのプロバイダーであるクロス・リバー・セラピー社が発表した統計によると、米国の製薬業界の売上高は5,500億米ドルでした。2021年、アメリカ人は医薬品に5,769億米ドルを費やしており、2025年には6,050億米ドルから6,350億米ドルに増加すると予測されています。したがって、ヘルスケア支出の増加がチロシンキナーゼ阻害剤市場の今後の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のチロシンキナーゼ阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のチロシンキナーゼ阻害剤市場：成長率分析
• 世界のチロシンキナーゼ阻害剤市場の実績：規模と成長, 2019-2024
• 世界のチロシンキナーゼ阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界のチロシンキナーゼ阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のチロシンキナーゼ阻害剤市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• BCR-ABLチロシンキナーゼ阻害剤
• 上皮成長因子受容体（EGFR）チロシンキナーゼ阻害剤
• 血管内皮増殖因子受容体（VEGFR）チロシンキナーゼ阻害剤
• その他のタイプ
• 世界のチロシンキナーゼ阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 独立薬局
• オンライン薬局
• 世界のチロシンキナーゼ阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性骨髄性白血病（CML）
• 肺がん
• 乳がん
• 腎細胞がん
• その他の用途
• 世界のチロシンキナーゼ阻害剤市場、タイプ別サブセグメンテーション：BCR-ABLチロシンキナーゼ阻害剤、実績と予測, 2019-2024, 2024-2029F, 2034F
• イマチニブ
• ダサチニブ
• ニロチニブ
• ボスチニブ
• ポナチニブ
• 世界のチロシンキナーゼ阻害剤市場、タイプ別サブセグメンテーション：上皮成長因子受容体（EGFR）チロシンキナーゼ阻害剤、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲフィチニブ
• エルロチニブ
• アファチニブ
• オシメルチニブ
• ダコミチニブ
• 世界のチロシンキナーゼ阻害剤市場、タイプ別サブセグメンテーション：血管内皮増殖因子受容体（VEGFR）チロシンキナーゼ阻害剤、実績と予測, 2019-2024, 2024-2029F, 2034F
• ソラフェニブ
• スニチニブ
• パゾパニブ
• アキシチニブ
• レゴラフェニブ
• 世界のチロシンキナーゼ阻害剤市場、タイプ別サブセグメンテーション：その他のタイプ、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血小板由来成長因子受容体（PDGFR）阻害剤
• RETチロシンキナーゼ阻害剤
• 線維芽細胞増殖因子受容体（FGFR）阻害剤
• その他の新興チロシンキナーゼ阻害剤

第7章 地域別・国別分析

• 世界のチロシンキナーゼ阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のチロシンキナーゼ阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• チロシンキナーゼ阻害剤市場：競合情勢
• チロシンキナーゼ阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Private Limited. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca Plc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd
• Incyte Corporation
• Dr. Reddy's Laboratories Ltd.
• Exelixis Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• チロシンキナーゼ阻害剤市場2029：新たな機会を提供する国
• チロシンキナーゼ阻害剤市場2029：新たな機会を提供するセグメント
• チロシンキナーゼ阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Tyrosine kinase inhibitors (TKI) constitute a class of pharmaceuticals designed to impede multiple pathways through which protein kinases signal the transduction pathway's function. This targeted therapy is employed to selectively target and eliminate specific cancer cell types while preserving healthy cells.

The primary categories of tyrosine kinase inhibitors include BCR-ABL tyrosine kinase inhibitors, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, and others. BCR-ABL tyrosine kinase inhibitors specifically target the enzyme inhibiting BCR-ABL tyrosine kinases, crucial in the pathogenesis of chronic myelogenous leukemia (CML), serving as a first-line therapy for patients with CML. These inhibitors are distributed through various channels such as hospital pharmacies, independent pharmacies, and online pharmacies, and are applied in the treatment of conditions such as chronic myeloid leukemia (CML), lung cancer, breast cancer, renal cell cancer, and others.

The tyrosine kinase inhibitors market research report is one of a series of new reports from The Business Research Company that provides tyrosine kinase inhibitors market statistics, including tyrosine kinase inhibitors industry global market size, regional shares, competitors with a tyrosine kinase inhibitors market share, detailed tyrosine kinase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the tyrosine kinase inhibitors industry. This tyrosine kinase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tyrosine kinase inhibitors market size has grown strongly in recent years. It will grow from $58.03 billion in 2024 to $63.25 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to the discovery of tyrosine kinases, understanding of cancer signaling pathways, approval of imatinib (Gleevec), the clinical success of early TKIs, and investment in research and development

The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $88.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing healthcare investments, biomarker-driven therapies, drug delivery innovations, precision medicine paradigm, pediatric oncology focus. Major trends in the forecast period include resistance mitigation strategies, development of CNS-penetrant tkis, non-oncology applications, liquid biopsies for monitoring, health economic considerations.

The anticipated rise in cancer prevalence is set to drive the growth of the tyrosine kinase inhibitors market in the future. Cancer, a diverse group of diseases characterized by uncontrolled cell growth, poses a significant health challenge as abnormal cells proliferate, invade neighboring tissues, and potentially spread to other organs. Tyrosine kinase inhibitors play a crucial role in targeted therapy by blocking specific tyrosine kinases, thereby inhibiting the growth of cancer cells. As of January 2023, the American Cancer Society reported an increase in cancer cases from 1,898,160 in 2021 to 1,958,310 in 2023, representing a growth of 3.16%. This surge in cancer cases is a key driver fueling the growth of the tyrosine kinase inhibitors market.

The growth of the tyrosine kinase inhibitors market is being driven by an increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. This spending supports the development and use of tyrosine kinase inhibitors, which are targeted therapies for specific cancer types and other conditions. For example, in September 2024, statistics published by Cross River Therapy, a US-based provider of ABA therapy services, revealed that the U.S. pharmaceutical industry generated $550 billion in revenue. In 2021, Americans spent $576.9 billion on medicine, and projected spending is expected to rise to between $605 and $635 billion by 2025. Therefore, the increase in healthcare spending is propelling the growth of the tyrosine kinase inhibitors market moving forward.

Product innovations are becoming a significant trend in the tyrosine kinase inhibitor market. Major companies in this sector are adopting new technologies to maintain their competitive edge. For example, in February 2023, Xspray Pharma AB, a Swedish pharmaceutical firm, entered into an agreement with EVERSANA, a US-based life sciences service provider, to support the U.S. launch and commercialization of its first innovative cancer therapy, Dasynoc. This therapy is aimed at treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasynoc introduces a new and unique treatment option for CML and ALL patients within the $3.5 billion U.S. tyrosine kinase inhibitor market. It marks a significant advancement for CML patients; retrospective registry data presented at ASH 2022 indicated a 5-year overall survival rate of 79% for those treated with both a tyrosine kinase inhibitor (TKI) and a proton pump inhibitor (PPI) like omeprazole, compared to 94% for patients receiving TKI alone.

Major companies in the neoantigens targeted therapies market are strategically forming partnerships to establish robust and comprehensive intellectual property. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. In March 2023, Mithra Pharmaceuticals SA, a Belgian-based biotechnology company, entered into a partnership with BCI Pharma, a France-based pharmaceutical technology company. The collaboration aims to develop novel tyrosine kinase inhibitors, focusing primarily on endometriosis and cancer, including orphan indications such as triple-negative breast cancer (TNBC).

In June 2022, Bristol Myers Squibb, a US-based pharmaceutical company, completed the acquisition of Turning Point Therapeutics Inc. for an undisclosed amount. This strategic move enables Bristol Myers Squibb to expand its leading oncology franchise and fully harness the potential of the precision oncology platform for enhancing standard cancer treatment. Turning Point Therapeutics Inc., a US-based pharmaceutical company, specializes in manufacturing precision medicines for cancer and other diseases, including tyrosine kinase inhibitors.

Major companies operating in the tyrosine kinase inhibitors market include Pfizer Inc., Johnson And Johnson Private Limited., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd, Incyte Corporation, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Glenmark Pharmaceuticals Ltd, Blueprint Medicines Corporation, Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., ArQule Inc.

North America was the largest region in the tyrosine kinase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tyrosine kinase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tyrosine kinase inhibitors market consists of sales of gleevec, dasatinib (Sprycel), nilotinib (Tasigna), erlotinib (Tarceva), crizotinib (Xalkori), and sunitinib (Sutent). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tyrosine Kinase Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tyrosine kinase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tyrosine kinase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tyrosine kinase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: BCR-ABL Tyrosine Kinase Inhibitor; Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors; Other Types
• 2) By Distribution Channel: Hospital Pharmacy; Independent Pharmacies; Online Pharmacies
• 3) By Application: Chronic Myeloid Leukemia (CML); Lung Cancer; Breast Cancer; Renal Cell Cancer; Other Applications
• Subsegments:
• 1) By BCR-ABL Tyrosine Kinase Inhibitor: Imatinib; Dasatinib; Nilotinib; Bosutinib; Ponatinib
• 2) By Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: Gefitinib; Erlotinib; Afatinib; Osimertinib; Dacomitinib
• 3) By Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors: Sorafenib; Sunitinib; Pazopanib; Axitinib; Regorafenib
• 4) By Other Types: Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors; RET Tyrosine Kinase Inhibitors; Fibroblast Growth Factor Receptor (FGFR) Inhibitors; Other Emerging Tyrosine Kinase Inhibitors
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson Private Limited.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tyrosine Kinase Inhibitors Market Characteristics

3. Tyrosine Kinase Inhibitors Market Trends And Strategies

4. Tyrosine Kinase Inhibitors Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Tyrosine Kinase Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tyrosine Kinase Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tyrosine Kinase Inhibitors Market Growth Rate Analysis
• 5.4. Global Tyrosine Kinase Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tyrosine Kinase Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tyrosine Kinase Inhibitors Total Addressable Market (TAM)

6. Tyrosine Kinase Inhibitors Market Segmentation

• 6.1. Global Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BCR-ABL Tyrosine Kinase Inhibitors
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
• Other Type
• 6.2. Global Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Independent Pharmacies
• Online Pharmacies
• 6.3. Global Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Renal Cell Cancer
• Other Applications
• 6.4. Global Tyrosine Kinase Inhibitors Market, Sub-Segmentation Of BCR-ABL Tyrosine Kinase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imatinib
• Dasatinib
• Nilotinib
• Bosutinib
• Ponatinib
• 6.5. Global Tyrosine Kinase Inhibitors Market, Sub-Segmentation Of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gefitinib
• Erlotinib
• Afatinib
• Osimertinib
• Dacomitinib
• 6.6. Global Tyrosine Kinase Inhibitors Market, Sub-Segmentation Of Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sorafenib
• Sunitinib
• Pazopanib
• Axitinib
• Regorafenib
• 6.7. Global Tyrosine Kinase Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors
• RET Tyrosine Kinase Inhibitors
• Fibroblast Growth Factor Receptor (FGFR) Inhibitors
• Other Emerging Tyrosine Kinase Inhibitors

7. Tyrosine Kinase Inhibitors Market Regional And Country Analysis

• 7.1. Global Tyrosine Kinase Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tyrosine Kinase Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tyrosine Kinase Inhibitors Market

• 8.1. Asia-Pacific Tyrosine Kinase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tyrosine Kinase Inhibitors Market

• 9.1. China Tyrosine Kinase Inhibitors Market Overview
• 9.2. China Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tyrosine Kinase Inhibitors Market

• 10.1. India Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tyrosine Kinase Inhibitors Market

• 11.1. Japan Tyrosine Kinase Inhibitors Market Overview
• 11.2. Japan Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tyrosine Kinase Inhibitors Market

• 12.1. Australia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tyrosine Kinase Inhibitors Market

• 13.1. Indonesia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tyrosine Kinase Inhibitors Market

• 14.1. South Korea Tyrosine Kinase Inhibitors Market Overview
• 14.2. South Korea Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tyrosine Kinase Inhibitors Market

• 15.1. Western Europe Tyrosine Kinase Inhibitors Market Overview
• 15.2. Western Europe Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tyrosine Kinase Inhibitors Market

• 16.1. UK Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tyrosine Kinase Inhibitors Market

• 17.1. Germany Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tyrosine Kinase Inhibitors Market

• 18.1. France Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tyrosine Kinase Inhibitors Market

• 19.1. Italy Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tyrosine Kinase Inhibitors Market

• 20.1. Spain Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tyrosine Kinase Inhibitors Market

• 21.1. Eastern Europe Tyrosine Kinase Inhibitors Market Overview
• 21.2. Eastern Europe Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tyrosine Kinase Inhibitors Market

• 22.1. Russia Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tyrosine Kinase Inhibitors Market

• 23.1. North America Tyrosine Kinase Inhibitors Market Overview
• 23.2. North America Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tyrosine Kinase Inhibitors Market

• 24.1. USA Tyrosine Kinase Inhibitors Market Overview
• 24.2. USA Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tyrosine Kinase Inhibitors Market

• 25.1. Canada Tyrosine Kinase Inhibitors Market Overview
• 25.2. Canada Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tyrosine Kinase Inhibitors Market

• 26.1. South America Tyrosine Kinase Inhibitors Market Overview
• 26.2. South America Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tyrosine Kinase Inhibitors Market

• 27.1. Brazil Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tyrosine Kinase Inhibitors Market

• 28.1. Middle East Tyrosine Kinase Inhibitors Market Overview
• 28.2. Middle East Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tyrosine Kinase Inhibitors Market

• 29.1. Africa Tyrosine Kinase Inhibitors Market Overview
• 29.2. Africa Tyrosine Kinase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tyrosine Kinase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tyrosine Kinase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tyrosine Kinase Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Tyrosine Kinase Inhibitors Market Competitive Landscape
• 30.2. Tyrosine Kinase Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Private Limited. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Tyrosine Kinase Inhibitors Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca Plc.
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. Astellas Pharma Inc.
• 31.12. Eisai Co. Ltd
• 31.13. Incyte Corporation
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Exelixis Inc.

32. Global Tyrosine Kinase Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tyrosine Kinase Inhibitors Market

34. Recent Developments In The Tyrosine Kinase Inhibitors Market

35. Tyrosine Kinase Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Tyrosine Kinase Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tyrosine Kinase Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tyrosine Kinase Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer